<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        295-325-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LISART PLUS  80 MG/12.5 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROCHLOROTHIAZIDE, TELMISARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80 , 12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        59.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C03AA03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        C09CA07
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LISART PLUS is a combination of two active substances, Telmisartan and Hydrochlorothiazide in one tablet. Both of these substances help to control high blood pressure.</p><p>Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists. Angiotensin II is a substance produced in your body which causes your blood vessels to narrow, thus increasing your blood pressure. Telmisartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.</p><p>Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure.</p><p>High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly measure blood pressure to verify if it is within the normal range.</p><p>LISART PLUS is used to<strong> </strong>treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when Telmisartan is used alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take LISART PLUS</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to Telmisartan or any other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to hydrochlorothiazide or to any other sulfonamide-derived medicines.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant. (It is also better to avoid LISART PLUS in early pregnancy &ndash; see pregnancy section.)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor determines that you have low potassium levels or high calcium levels in your blood that do not get better with treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>If any of the above applies to you, tell your doctor or pharmacist before taking LISART PLUS .</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor if you are suffering or have ever suffered from any of the following conditions or illnesses:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy (&lsquo;water tablets&rsquo;), low-salt diet, diarrhoea, or vomiting.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney disease or kidney transplant.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart trouble.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gout.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised aldosterone levels (water and salt retention in the body along with imbalance of various blood minerals).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic lupus erythematosus (also called &quot;lupus&quot; or &quot;SLE&quot;) a disease where the body&#39;s immune system attacks the body.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient hydrochlorothiazide can cause an unusual reaction, resulting in a decrease in vision and eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking LISART PLUS . This can lead to permanent vision impairment, if not treated.</p><p><strong>Talk to your doctor before taking LISART PLUS :</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading &ldquo;Do not take LISART PLUS &rdquo;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking digoxin.</p><p>You must tell your doctor if you think you are (or <u>might become</u>) pregnant. LISART PLUS is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>Treatment with hydrochlorothiazide may cause electrolyte imbalance in your body. Typical symptoms of fluid or electrolyte imbalance include dry mouth, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, nausea (feeling sick), vomiting, tired muscles, and an abnormally fast heart rate (faster than 100 beats per minute). If you experience any of these, you should tell your doctor.</p><p>You should also tell your doctor, if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal.</p><p>In case of surgery or anaesthesia, you should tell your doctor that you are taking LISART PLUS .</p><p>LISART PLUS may be less effective in lowering the blood pressure in black patients.</p><p><strong>Children and adolescents</strong></p><p>The use of LISART PLUS in children and adolescents up to the age of 18 years is not recommended.</p><p><strong>Other medicines and LISART PLUS </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change the dose of these other medicines or take other precautions. In some cases you may have to stop taking one of the medicines. This applies especially to the medicines listed below taken at the same time with LISART PLUS :</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium containing medicines to treat some types of depression.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines associated with low blood potassium (hypokalaemia) such as other diuretics, (&#39;water tablets&#39;), laxatives (e.g. castor oil), corticosteroids (e.g. prednisone), ACTH (a hormone), amphotericin (an antifungal medicine), carbenoxolone (used to treat mouth ulcers), penicillin G sodium (an antibiotic), and salicylic acid and derivatives.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, ACE inhibitors that may increase blood potassium levels.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart medicines (e.g. digoxin) or medicines to control the rhythm of your heart (e.g. quinidine, disopyramide).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used for mental disorders (e.g. thioridazine, chlorpromazine, levomepromazine).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines used to treat high blood pressure, steroids, painkillers, medicines to treat cancer, gout, or arthritis, and vitamin D supplements.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &quot;Do not take LISART PLUS &quot; and &quot;Warnings and precautions&quot;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin.</p><p>LISART PLUS may increase the blood pressure lowering effect of other medicines used to treat high blood pressure or of medicines with blood pressure lowering potential (e.g. baclofen, amifostine). Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants. You may notice this as dizziness when standing up. You should consult with your doctor if you need to adjust the dose of your other medicine while taking LISART PLUS .</p><p>The effect of LISART PLUS may be reduced when you take NSAIDs (non-steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen) &nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Pregnancy: </strong>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking LISART PLUS before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of LISART PLUS . LISART PLUS is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><strong>Breast-feeding: </strong>Tell your doctor if you are breast-feeding or about to start breast-feeding. LISART PLUS is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.</p><p><strong>Driving and using machines</strong></p><p>Some people feel dizzy or tired when taking LISART PLUS . If you feel dizzy or tired, do not drive or operate machinery.</p><p><strong>Important information about some of the ingredients of </strong><strong>LISART PLUS:</strong></p><p>LISART PLUS contains Lactose and Mannitol.&nbsp;They are type of sugar. If you have been told by your doctor that you cannot tolerate some sugars (have an intolerance to some sugars), talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take LISART PLUS exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose of LISART PLUS is one tablet a day. Try to take the tablet at the same time each day.</p><p>You can take LISART PLUS with or without food. The tablets should be swallowed with some water or other non-alcoholic drink. It is important that you take LISART PLUS every day until your doctor tells you otherwise.</p><p>If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once a day.</p><p><strong>If you take more LISART PLUS than you should</strong></p><p>If you accidentally take too many tablets, contact your doctor, pharmacist, or your nearest hospital emergency department immediately.</p><p><strong>If you forget to take LISART PLUS </strong></p><p>If you forget to take a dose, do not worry. Take it as soon as you remember then carry on as before. If you do not take your tablet on one day, take your normal dose on the next day. Do not take a double dose to make up for forgotten individual doses.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some side effects can be serious and need immediate medical attention:</strong></p><p>You should see your doctor immediately if you experience any of the following symptoms:</p><p>Sepsis* (often called &ldquo;blood poisoning&rdquo;, is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare (may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately. If these effects are not treated they could be fatal. Increased incidence of sepsis has been observed with telmisartan only, however cannot be ruled out for LISART PLUS .</p><p><strong>Possible side effects of LISART PLUS :</strong></p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>Dizziness.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people):</strong></p><p>Decreased blood potassium levels, anxiety, fainting (syncope), sensation of tingling, pins and needles (paraesthesia), feeling of spinning (vertigo), fast heart beat (tachycardia), heart rhythm disorders, low blood pressure, a sudden fall in blood pressure when you stand up, shortness of breath (dyspnoea), diarrhoea, dry mouth, flatulence, back pain, muscle spasm, muscle pain, erectile dysfunction (inability to get or keep an erection), chest pain, increased blood uric acid levels.</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people):</strong></p><p>Inflammation of the lung (bronchitis), activation or worsening of systemic lupus erythematosus (a disease where the body&#39;s immune system attacks the body, which causes joint pain, skin rashes and fever); sore throat, inflamed sinuses, feeling sad (depression), difficulty falling asleep (insomnia), impaired vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick, inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience these side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities, muscle cramps, flu-like-illness, pain, increased levels of uric acid, low levels of sodium, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood.</p><p>Adverse reactions reported with one of the individual components may be potential adverse reactions with LISART PLUS , even if not observed in clinical trials with this product.</p><p><strong>Telmisartan</strong></p><p>In patients taking telmisartan alone, the following additional side effects have been reported:</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people):</strong></p><p>Upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), urinary tract infections, deficiency in red blood cells (anemia), high potassium levels, slow heart rate (bradycardia), kidney impairment including acute kidney failure, weakness, cough.</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people):</strong></p><p>Sepsis* (often called &quot;blood poisoning&quot;, is a severe infection with whole-body inflammatory response which can lead to death), low platelet count (thrombocytopenia), increase in certain white blood cells (eosinophilia), serious allergic reaction (e.g. hypersensitivity, anaphylactic reaction, drug rash), low blood sugar levels (in diabetic patients), upset stomach, eczema (a skin disorder), arthrosis, inflammation of the tendons, decreased haemoglobin (a blood protein), somnolence.</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people):</strong></p><p>Progressive scarring of lung tissue (interstitial lung disease)**.</p><p>* The event may have happened by chance or could be related to a mechanism currently not known.</p><p>** Cases of progressive scarring of lung tissue have been reported during intake of LISART PLUS . However, it is not known whether LISART PLUS was the cause.</p><p><strong>Hydrochlorothiazide<u> </u></strong></p><p>In patients taking hydrochlorothiazide alone, the following additional side effects have been reported:</p><p><strong>Side effects of unknown frequency</strong> (frequency cannot be estimated from the available data): Inflammation of the salivary gland, decreases in the number of cells in the blood, including low red and white blood cell count, low platelet count (thrombocytopenia), serious allergic reactions (e.g. hypersensitivity, anaphylactic reaction), decreased or loss of appetite, restlessness, light &shy;headedness, blurred or yellowing of vision, decrease in vision and eye pain (possible signs of acute myopia or acute-angle closure glaucoma), inflammation of blood vessels (vasculitis necrotising), inflamed pancreas, upset stomach, yellowing of the skin or eyes (jaundice), lupus-like syndrome (a condition mimicking a disease called systemic lupus erythematosus where the body&#39;s immune system attacks the body); skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, or blistering and peeling of the top layer of skin (toxic epidermal necrolysis), weakness, kidney inflammation or impaired kidney function, glucose in the urine (glycosuria), fever, impaired electrolyte balance, high blood cholesterol levels, decreased blood volume, increased levels of glucose, or fat in the blood.</p><p><strong>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t store above 30&deg;C</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep in the original pack to protect from light and moisture.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use after the expiry date printed on the package</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Telmisartan/ Hydrochlorothiazide 40/12.5 mg Tablets </strong></p><p>Each tablet contains Telmisartan (USP) 40 mg and Hydrochlorothiazide (USP) 12.5 mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Telmisartan/ Hydrochlorothiazide 80/12.5 mg Tablets</strong></p><p>Each tablet contains Telmisartan (USP) 80 mg and Hydrochlorothiazide (USP) 12.5 mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are Mannitol, Povidone, Meglumine, Sodium Hydroxide, Magnesium Stearate, Lactose Monohydrate, Microcrystalline Cellulose, Maize Starch, Sodium Starch Glycolate (Type A), Iron Oxide Red (Sicovit Red 30E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tablet
•	LISART PLUS 40/12.5 mg Tablets 
Red and white to off white, oval shaped, uncoated, biconvex, beveled edge, bilayered tablets, debossed with “RC90” on one side and plain on the other side. The white to off white layer may occasionally contain red tinge /specks.
•	LISART PLUS 80/12.5 mg Tablets 
Yellow and white to off white, oblong shaped, uncoated, biconvex, bilayered tablets debossed with “RC91” on one side and plain on the other side. The white to off white layer may contain yellow tinge /specks.
Pack contains (28) tablets of LISART PLUS 40/12.5 mg or 80/12.5 mg 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O. Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p>For any information about this medicinal product, please contact the local representative of &nbsp;marketing authorisation holder:</p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ليزارت بلس مركب مزدوج لمادتين فعالتين هما تلميسارتان وهيدروكلورثيازيد في قرص واحد. كلتا هاتين المادتين تساعدا على السيطرة على ضغط الدم العالي.</p><p dir="RTL">تلميسارتان ينتمي الى فئة من الأدوية تعرف باسم مضادات مستقبلات أنجيوتنسين II. أنجيوتنسين II هو عبارة عن مادة تنتج في الجسم والتي تسبب تضييق الأوعية الدموية، وبالتالي زيادة ضغط الدم. يمنع تلميسارتان تأثير أنجيوتنسين II بحيث تسترخي الأوعية الدموية، وينخفض ضغط الدم.</p><p dir="RTL">هيدروكلورثيازيد ينتمي إلى مجموعة من الأدوية تسمى مدرات البول ثيازيد، مما يسبب زيادة إخراج البول، مما يؤدي إلى خفض ضغط الدم.</p><p dir="RTL">ارتفاع ضغط الدم، إذا لم يعالج، يمكن أن يتلف الأوعية الدموية في العديد من الأجهزة، التي يمكن أن تؤدي أحيانا إلى نوبة قلبية، فشل القلب أو الكلي والسكتة الدماغية، أو العمى. عادة لا تكون هناك أي أعراض لارتفاع ضغط الدم قبل حدوث الضرر. وبالتالي فإنه من المهم قياس ضغط الدم بشكل منتظم للتحقق ما إذا كان ضمن المعدل الطبيعي.</p><p dir="RTL">يستخدم ليزارت بلس لعلاج ارتفاع ضغط الدم الأساسي (ارتفاع ضغط الدم) في البالغين. الذين لم يتم السيطرة على ضغط الدم لديهم عند استخدام تلميسارتان منفرداً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ليزارت بلس إذا: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لديك حساسية من تلميسارتان أو أي مكونات أخرى من هذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من هيروكلورثيازيد أو أي من أدوية مشتقة من سالفوناميد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتي حاملا لأكثر من 3 أشهر. (كما أنه من الافضل تجنب ليزارت بلس في المرحلة المبكرة من الحمل &ndash; انظر قسم الحمل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل حاده في الكبد مثل توقف العصارة الصفراء أو انسداد القنوات الصفراوية (مشاكل مع تصريف الصفراء من الكبد والمرارة) أو أي من أمراض الكبد الشديدة الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض كلوي شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدد الطبيب أن لديك مستويات منخفضة من البوتاسيوم أو مستويات عالية من الكالسيوم بالدم والتي لا تتحسن مع العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض السكري أو اختلال وظائف الكلى وتتم المعالجة باستخدام أدوية خفض ضغط الدم التي تحتوي على أليسكيرين.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك، أخبر طبيبك أو الصيدلي قبل تناول ليزارت بلس .</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك إذا كنت تعاني أو عانيت في أي وقت مضى من أي من الحالات أو الأمراض التالية:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضغط دم منخفض (هبوط)، من المحتمل أن يحدث إذا كنت مصاب بالجفاف (فقدان الجسم لكمية بالغة من الماء) أو لديك نقص أملاح بسبب العلاج بمدرات البول (أقراص الماء)، أو اتباع نظام غذائي قليل الملح، والإسهال، أو القيء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أمراض الكلى أو زرع الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الشريان الكلوي (تضييق الأوعية الدموية في احدى أو كلا الكليتين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متاعب في القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض النقرص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات الألدوستيرون العالية (احتباس الماء والملح في الجسم مع اختلال توازن المعادن المختلفة في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمامية الجهازية (وتسمى أيضا &quot;داء الذئبة&quot; أو &quot;SLE&quot;) مرض حيث يهاجم الجهاز المناعي الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن تسبب المادة الفعالة هيدروكلورثيازيد رد فعل غير عادي، بما يؤدي إلى انخفاض في الرؤية وآلام بالعين. يمكن أن تكون هذه أعراض زيادة الضغط في العين ويمكن أن يحدث في غضون ساعات إلى أسابيع من تناول ليزارت بلس . هذا يمكن أن يؤدي إلى ضعف دائم بالرؤية، إذا لم يعالج</p><p dir="RTL"><strong>تحدث إلى طبيبك قبل تناول ليزارت بلس :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي من الأدوية التالية التي تستخدم لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبط&nbsp;الانزيم المحول للأنجيوتنسين ((ACE :(على سبيل المثال إنالابريل، لايسينوبريل، راميبريل)، ولا سيما إذا كان لديك مشاكل في الكلى المتصلة بالسكري.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">قد يراجع طبيبك وظيفة الكلى لديك وضغط الدم، وكمية الشوارد (مثل البوتاسيوم) في الدم على فترات منتظمة. انظر أيضا المعلومات تحت عنوان &quot;لا تتناول ليزارت بلس &quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الديجوكسين.</p><p dir="RTL">يجب إخبار الطبيب إذا كنت تعتقدين أنك (أو قد تصبحين) حاملا. لا ينصح بتناول ليزارت بلس في مرحلة مبكرة من الحمل، ويجب عدم تناوله إذا كنتي حاملا لأكثر من 3 أشهر، لأنها قد تسبب ضررا بالغا لطفلك إذا ما استخدمت في تلك المرحلة (انظر قسم الحمل).</p><p dir="RTL">العلاج مع هيدروكلورثيازيد قد يسبب عدم توازن العناصر بالسوائل في جسمك. وتشمل الأعراض النمطية لاختلال السوائل جفاف الفم، والضعف والخمول والنعاس والأرق، وآلام في العضلات أو تشنجات، غثيان (الشعور المرضي)، والتقيؤ، وتعب العضلات ، وسرعة دقات القلب بشكل غير طبيعي (أسرع من 100 نبضة في الدقيقة). إذا كنت تواجه أي من هذه، يجب إخبار الطبيب بذلك.</p><p dir="RTL">يجب عليك أيضا إخبار الطبيب، إذا واجهت زيادة حساسية الجلد لأشعة الشمس مع أعراض حروق الشمس (مثل احمرار، حكة، تورم، وظهور تقرحات) التي تحدث بسرعة أكثر من المعتاد.</p><p dir="RTL">في حالة الجراحة أو التخدير، عليك أن تخبر طبيبك أنك تتناول ليزارت بلس .</p><p dir="RTL">قد يكون ليزارت بلس أقل فعالية في خفض ضغط الدم في المرضى ذوي البشرة الداكنة.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا ينصح استخدام ليزارت بلس في الأطفال والمراهقين حتى سن 18 سنة.</p><p dir="RTL"><strong>الأدوية الأخرى وليزارت بلس </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تأخذ أي أدوية أخرى. قد يحتاج الطبيب إلى تغيير جرعة من هذه الأدوية الأخرى أو اتخاذ الاحتياطات الأخرى. في بعض الحالات قد تضطر الي التوقف عن تناول واحد من الأدوية. هذا ينطبق بشكل خاص على الأدوية المذكورة أدناه التي تم تناولها في الوقت نفسه مع ليزارت بلس :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تحتوي على ليثيوم لعلاج بعض أنواع الاكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المرتبطة مع انخفاض البوتاسيوم في الدم (نقص بوتاسيوم الدم) مثل مدرات البول الأخرى، (أقراص الماء)، الملينات (مثل زيت الخروع)، الستيرويدات (مثل بريدنيزون)، ACTH (هرمون)، أمفوتيريسين (دواء مضاد للفطريات)، كربينوكسولون (يستخدم لعلاج تقرحات الفم)، البنسلين G الصوديوم (مضاد حيوي)، وحمض الساليسيليك ومشتقاته</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول التي تتجنب البوتاسيوم، المكملات الغذائية بالبوتاسيوم وبدائل الملح التي تحتوي على البوتاسيوم، ومثبطات&nbsp;الانزيم المحول للأنجيوتنسين (ACE)&ndash; التي قد تزيد من مستويات البوتاسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية القلب (مثل الديجوكسين) أو الأدوية للسيطرة على إيقاع قلبك (مثل كينيدين، ديسوبيراميد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة لعلاج الاضطرابات العقلية (مثل ثيوريدازين، الكلوربرومازين، ليفوميبرومازين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المستخدمة لعلاج ارتفاع ضغط الدم، والمنشطات، والمسكنات، وأدوية لعلاج السرطان، والنقرس، والتهاب المفاصل، وفيتامين (د).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ مثبطات&nbsp;الانزيم المحول للأنجيوتنسين (ACE)&ndash; أو أليسكيرين (انظر أيضا المعلومات تحت عناوين &quot;لا تتناول ليزارت بلس &quot; و &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين.</p><p dir="RTL">ليزارت بلس قد يزيد من تأثير خفض ضغط الدم للأدوية الأخرى المستخدمة لعلاج ارتفاع ضغط الدم أو الأدوية الخافضة لضغط الدم (على سبيل المثال باكلوفين، اميفوستين). وعلاوة على ذلك، يمكن أن يتفاقم انخفاض ضغط الدم عن طريق الكحول، الباربيتورات، المخدرات أو العقاقير المضادة للاكتئاب. قد تلاحظ هذا الشعور بالدوخة عند الوقوف. يجب استشارة الطبيب إذا كنت تحتاج إلى ضبط جرعة الأدوية الأخرى الخاصة بك في حين تتناول ليزارت بلس .</p><p dir="RTL">ربما ينخفض تأثير ليزارت بلس عند أخذ المسكنات (غير الستيرويدية الأدوية المضادة للالتهابات، مثل الأسبرين أو الإيبوبروفين) أو الكورتيكوستيرويدات.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>الحمل: </strong>يجب إخبار الطبيب إذا كنت تعتقدين أنك (أو قد تصبحين) حاملا. عادة سوف ينصحك طبيبك الخاص ان تتوقفي عن تناول ليزارت بلس قبل أن تصبحي حاملا أو في أقرب وقت تعلمين فيه أنك حامل وسوف ينصحك بتناول دواء آخر بدلا من ليزارت بلس .</p><p dir="RTL">&nbsp;لا ينصح بليزارت بلس في مرحلة مبكرة من الحمل، ويجب عدم تناوله بعد مرور أكثر من 3 أشهر على الحمل، لأنها قد تسبب ضررا بالغا لطفلك إذا ما استخدم بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية: </strong>أخبري طبيبك إذا كنتي ترضعي الرضاعة الطبيعية أو على وشك القيام بالرضاعة الطبيعية. لا ينصح ليزارت بلس للأمهات الذين يرضعون الرضاعة الطبيعية، والطبيب قد يختار علاج آخر بالنسبة لك إذا كنتي ترغبين في الإرضاع، وخاصة إذا كان طفلك حديث الولادة، أو ولدت قبل الأوان.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">بعض الناس يشعرون بالدوار أو التعب عند تناول ليزارت بلس . إذا كنت تشعر بالدوار أو التعب، لا تقود السيارة أو تشغل الآلات.</p><p dir="RTL"><strong>معلومات هامة حول بعض العناصر</strong><strong> </strong><strong>من ليزارت بلس</strong></p><p dir="RTL">ليزارت بلس يحتوي على لاكتوز و مانيتول. وهما من أنواع السكريات. إذا كان لديك أو قيل لك من قبل الطبيب أنه لا يمكن أن تتحمل بعض السكريات (لديك عدم التحمل لبعض السكريات)، تحدث مع طبيبك قبل تناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول ليزارت بلس تماما كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">الجرعة الموصى بها من ليزارت بلس هي قرص واحد في اليوم. حاول تناول القرص في نفس الوقت كل يوم.</p><p dir="RTL">يمكنك أن تتناول ليزارت بلس مع أو بدون الطعام. يجب ابتلاع الأقراص مع بعض الماء أو غيرها من المشروبات غير الكحولية. من المهم أن تتناول ليزارت بلس كل يوم حتى يخبرك طبيبك خلاف ذلك.</p><p dir="RTL">إذا كان الكبد لا يعمل بشكل صحيح، يجب ألا تتجاوز الجرعة المعتادة 40 ملجم / 12.5 ملجم مرة واحدة يوميا.</p><p dir="RTL"><strong>إذا تناولت ليزارت بلس أكثر</strong><strong> </strong><strong>مما يجب</strong></p><p dir="RTL">إذا تناولت الكثير من الأقراص عن طريق الخطأ، اتصل بطبيبك أو الصيدلي، أو أقرب قسم للطوارئ في المستشفى على الفور.</p><p dir="RTL"><strong>إذا نسيت تناول</strong><strong> </strong><strong>ليزارت بلس </strong></p><p dir="RTL">إذا نسيت أن تتناول جرعة، لا تقلق. تناولها حالما تتذكر ثم استمر كما كان من قبل. إذا لم تتناول القرص في يوم ما، تناول الجرعة العادية الخاصة بك في اليوم التالي. لا تتناول جرعة مضاعفة لتعويض الجرعات المنسية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب ليزارت بلس في آثار جانبية، على الرغم من ذلك فأنها لا تحدث للجميع.</p><p dir="RTL"><strong>بعض الآثار الجانبية يمكن أن تكون خطيرة وتحتاج إلى عناية طبية فورية:</strong></p><p dir="RTL">يجب مراجعة الطبيب فورا إذا كنت تواجه أي من الأعراض التالية:</p><p dir="RTL">تعفن الدم * (غالبا ما تسمى &quot;تسمم الدم&quot;، هو عدوى شديدة مع استجابة التهابية بكامل الجسم)، وتورم سريع في الجلد والغشاء المخاطي (وذمة وعائية)؛ هذه الآثار الجانبية نادرة (قد تؤثر على ما يصل إلى 1 في 1.000 شخص) ولكنها خطيرة للغاية ويتعين على المرضى التوقف عن تناول الدواء ومراجعة الطبيب على الفور. إذا لم يتم معالجة هذه الآثار التي يمكن أن تكون قاتلة.</p><p dir="RTL">لوحظ تزايد احتمالية تعفن الدم مع استخدام التلميسارتان منفرداً، ومع ذلك لا يمكن تجاهلها مع ليزارت بلس</p><p dir="RTL"><strong>الآثار الجانبية المحتملة لليزارت بلس:</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 في كل 10 اشخاص):</strong></p><p dir="RTL">دوخة</p><p dir="RTL"><strong>الآثار الجانبية الغير شائعة (قد تؤثر على ما يصل إلى 1 في كل 100 شخص):</strong></p><p dir="RTL">انخفاض مستويات البوتاسيوم في الدم، والقلق، والإغماء (الغشيان)، والإحساس بالوخز والدبابيس والإبر (مذل)، والشعور بالدوران (الدوار)، ضربات القلب السريعة (عدم انتظام دقات القلب)، واضطرابات ضربات القلب، وانخفاض ضغط الدم، وهبوط مفاجئ في ضغط الدم عند الوقوف، وضيق في التنفس (ضيق التنفس)، والإسهال، جفاف الفم، وانتفاخ البطن، وآلام الظهر، وتشنج العضلات، وآلام في العضلات، وعدم القدرة على الانتصاب (عدم القدرة على الحصول أو الحفاظ على الانتصاب)، ألم في الصدر، وزيادة مستويات حمض اليوريك في الدم.</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى 1 في كل 1.000 شخص): </strong></p><p dir="RTL">التهاب الرئة (التهاب الشعب الهوائية)، وتنشيط أو تفاقم الذئبة الحمامية الجهازية (مرض يهاجم الجهاز المناعي للجسم، مما يسبب آلام المفاصل، والطفح الجلدي، والحمى). التهاب الحلق والجيوب الملتهبة، والشعور بالحزن (الاكتئاب)، صعوبة في النوم (الأرق)، ضعف البصر، وصعوبة التنفس، آلام في البطن، والإمساك والانتفاخ (عسر الهضم)، الشعور بالغثيان، والتهابات المعدة (التهاب المعدة)، اختلال وظيفة الكبد (المرضى اليابانيين هم أكثر عرضة للتعرض لهذه الآثار الجانبية)، وتورم السريع من الجلد والغشاء المخاطي التي يمكن أن تؤدي أيضا إلى وفاة (وذمة وعائية أيضا مع نتائج قاتلة)، احمرار في الجلد ، وأمراض الحساسية مثل الحكة أو الطفح الجلدي، وزيادة التعرق، والشرى (الأرتكاريا)، وآلام المفاصل (ألم مفصلي) وآلام في الأطراف، وتشنجات العضلات، واعراض تشبه مرض الانفلونزا،&nbsp; الألم، وزيادة مستويات حمض اليوريك ، ومستويات منخفضة من الصوديوم، وزيادة مستويات الكرياتينين، والإنزيمات الكبدية أو الكرياتين فسفوكيناز في الدم.</p><p dir="RTL">ردود فعل سلبية &nbsp;مع المكونات المنفردة قد تكون محتملة مع ليزارت بلس ، حتى لو لم تكن لوحظت في التجارب السريرية مع هذا المنتج.</p><p dir="RTL"><strong>تلميسارتان</strong></p><p dir="RTL">في المرضى الذين يتناولون تلميسارتان منفرداً الاعراض الجانبية التالية تم تقريرها</p><p dir="RTL"><strong>الآثار الجانبية الغير شائعة (قد تؤثر على ما يصل إلى 1 في كل 100 شخص):</strong></p><p dir="RTL">التهابات المسالك التنفسية العلوية (مثل التهاب الحلق، الجيوب الملتهبة، نزلات البرد)، التهابات المسالك البولية، ونقص في خلايا الدم الحمراء (فقر الدم)، مستويات عالية من البوتاسيوم،ضربات قلب بطيئة (بطء القلب)، ضعف في الكلى بما في ذلك فشل حاد في الكلى، الشعور بالضعف، والكحة.</p><p dir="RTL"><strong>الآثار الجانبية النادرة (قد تؤثر على ما يصل إلى 1 في كل 1.000 شخص): </strong></p><p dir="RTL">تعفن الدم * (غالبا ما تسمى &quot;تسمم الدم&quot;، هو عدوى شديدة مع استجابة التهابية بكامل الجسم التي يمكن أن تؤدي إلى الموت)، وانخفاض عدد الصفائح الدموية (الصفيحات)، وزيادة في بعض خلايا الدم البيضاء (فرط الحمضات)، رد فعل تحسسي شديد (رد فعل الحساسية والطفح الجلدي الناتج من الأدوية)، وانخفاض مستويات السكر في الدم (لدى مرضى السكري)، واضطرابات المعدة، الاكزيما (مرض جلدي)، التهاب المفاصل، التهاب الأوتار، وانخفاض الهيموجلوبين (بروتين الدم)، ونعاس.</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدا (قد تؤثر على ما يصل إلى 1 في كل 10.000 شخص):</strong></p><p dir="RTL">التندب التدريجي لأنسجة الرئة (مرض الرئة الخلالي) **.</p><p dir="RTL">* قد يكون حدث هذا الحدث بالصدفة أو يمكن أن تكون ذو صلة بآلية غير معروفة حاليا.</p><p dir="RTL">** تم الإبلاغ عن حالات تندب تدريجي لأنسجة الرئة أثناء تناول ليزارت بلس . ومع ذلك، فإنه ليس من المعروف ما إذا كان ليزارت بلس السبب.</p><p dir="RTL"><strong>هيدروكلورثيازيد</strong></p><p dir="RTL">في المرضى الذين يتناولون هيروكلورثيازيد منفرداً الاعراض الجانبية التالية تم تقريرها</p><p dir="RTL"><strong>الآثار الجانبية غير معروفة التكرار</strong> (لا يمكن تقدير تكرارها من البيانات المتاحة): التهاب الغدة اللعابية، والنقصان في عدد الخلايا في الدم، بما في ذلك انخفاض عدد خلايا الدم الحمراء والبيضاء، وانخفاض عدد الصفائح الدموية (الصفيحات)، ردود فعل حساسية خطيرة (على سبيل المثال فرط الحساسية، رد فعل تحسسي)، وانخفاض أو فقدان الشهية، والأرق، والدوار الخفيف، زغللة أو اصفرار الرؤية، وانخفاض في الرؤية وألم في العين (علامات محتملة من قصر النظر الحاد أو المياه الزرقاء المغلقة الزاوية الحادة)، والتهاب الأوعية الدموية (التهاب الأوعية الدموية التقرحي) والتهاب البنكرياس، اضطراب في المعدة، اصفرار الجلد أو العينين (اليرقان)، متلازمة شبيهة الذئبة (حالة محاكاة مرض يسمى الذئبة الحمامية الجهازية حيث يهاجم الجهاز المناعي للجسم على الجسم). اضطرابات الجلد مثل الأوعية الدموية الملتهبة في الجلد، وزيادة الحساسية لأشعة الشمس، أو ظهور تقرحات وتقشير الطبقة العليا من الجلد (انحلال البشرة السام)، والضعف، والتهاب الكلى أو اختلال وظائف الكلى، والجلوكوز في البول (بيلة سكرية)، والحمى، ضعف اختلال توازن المعادن المختلفة في الدم، وارتفاع مستويات الكوليسترول في الدم، وانخفاض حجم الدم، وزيادة مستويات الجلوكوز أو الدهون في الدم.</p><p dir="RTL"><strong>اذا عانيت من أي آثار جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي أعراض جانبية محتملة غير مدرجة في هذه النشرة .</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول ايدي ونظر الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يحفظ في درجة حرارة أكثر من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية للحماية من الضوء والرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استعمال ليزارت بلس بعد تاريخ انتهاء الصلاحية المذكور على العبوة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التخلص من الأدوية يجب ألا يكون عن طريق مياه الصرف الصحي أو النفايات المنزليه. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبه. هذة التدابير مساعده في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تلميسارتان/هيدروكلورثيازيد 40/12.5 ملجم </strong></p><p dir="RTL">كل قرص يحتوي على تلميسارتان (دستور الادوية الأمريكي) 40 ملجم وهيدروكلورثيازيد (دستور الادوية الأمريكي) 12.5 ملجم</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تلميسارتان/هيدروكلورثيازيد80/12.5 ملجم</strong></p><p dir="RTL">كل قرص يحتوي على تلميسارتان (دستور الادوية الأمريكي) 80 ملجم وهيدروكلورثيازيد (دستور الادوية الأمريكي) 12.5 ملجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى: مانيتول، بوفيدون، ميجلومين، هيدروكسيد الصوديوم، مغنيسيوم ستيرات، لاكتوز مونوهيدرات، ميكروكريستالين السليولوز، مايز ستارش، ستارش جليكولات الصوديوم (نوع A)، أكسيد الحديد الأحمر (Sicovit الأحمر 30E 172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>أقراص</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ليزارت بلس 40/12.5 ملجم أقراص:</strong></p><p dir="RTL">أقراص لونها أحمر وأبيض إلى أبيض داكن، بيضاوية الشكل، غير مغلفة، محدبة الوجهين، مشطوف الحافة، ثنائية الطبقات، محفور عليها &quot;RC90&quot; على جانب واحد ومنبسطة على الجانب الآخر. الطبقة البيضاء إلى الأبيض الداكن قد تحتوي في بعض الأحيان صبغة / بقع حمراء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ليزارت بلس 80/12.5 ملجم أقراص:</strong></p><p dir="RTL">&nbsp;أقراص لونها أصفر وأبيض إلى أبيض داكن، مستطيلة الشكل، غير مغلفة، محدبة الوجهين، ثنائية الطبقات، محفور عليها &quot;RC91&quot; على جانب واحد ومنبسطة على الجانب الآخر. الطبقة البيضاء إلى الأبيض الداكن قد تحتوي في بعض الأحيان صبغة / بقع صفراء.</p><p dir="RTL">عبوة تحتوي على (28) قرص من ليزارت بلس 40/12.5 ملجم أو 80/12.5 ملجم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lisart Plus 40/12.5 mg tablet
Lisart Plus 80/12.5 mg tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lisart Plus 40/12.5 mg tablet (Telmisartan/ Hydrochlorothiazide 40/12.5mg Tablets):
Each tablet contains 40 mg Telmisartan USP and 12.5 mg Hydrochlorothiazide USP.
Lisart Plus 80/12.5 mg tablet (Telmisartan/ Hydrochlorothiazide 80/12.5mg Tablets):
Each tablet contains 80 mg Telmisartan USP and 12.5 mg Hydrochlorothiazide USP.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
• Lisart Plus 40 mg/12.5 mg Tablets: Red and white to off white, Oval shaped, uncoated, biconvex,
beveled edge, bilayered tablets, debossed with “RC90” on one side and plain on the other side. The
white to off white layer may occasionally contain red tinge/ specks.
• Lisart Plus 80 mg/ 12.5 mg Tablets: Red and white to off white, oblong shaped, uncoated, biconvex,
bilayered tablets, debossed with “RC91” on one side and plain on the other side. The white to off
white layer may occasionally contain red tinge / specks.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.<br />Lisart Plus fixed dose combination (80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults<br />whose blood pressure is not adequately controlled on telmisartan alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />Lisart Plus should be taken in patients whose blood pressure is not adequately controlled by telmisartan<br />alone. Individual dose titration with each of the two components is recommended before changing to the<br />fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed<br />combination may be considered.<br />&bull; Lisart Plus 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not<br />adequately controlled by Lisart 40 mg<br />&bull; Lisart Plus 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not<br />adequately controlled by Lisart 80 mg<br />Special populations.</p><p><u>Patients with renal impairment</u><br />Periodic monitoring of renal function is advised (see section 4.4).</p><p><u>Patients with hepatic impairment</u><br />In patients with mild to moderate hepatic impairment the posology should not exceed Lisart Plus 40<br />mg/12.5 mg once daily. Lisart Plus is not indicated in patients with severe hepatic impairment. Thiazides<br />should be used with caution in patients with impaired hepatic function (see section 4.4).</p><p><u>Elderly patients</u><br />No dose adjustment is necessary.</p><p><u>Paediatric population</u><br />The safety and efficacy of Lisart Plus in children and adolescents aged below 18 have not been established.<br />No data are available.<br /><u>Method of administration</u><br />Lisart Plus tablets are for once-daily oral administration and should be taken with liquid, with or without<br />food.<br />Precautions to be taken before handling or administering the medicinal product<br />Lisart Plus should be kept in the sealed blister due to the hygroscopic property of the tablets. Tablets should<br />be taken out of the blister shortly before administration (see section 6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to any of the active substances or to any of the excipients listed in section 6.1.
• Hypersensitivity to other sulphonamide-derived substances (since hydrochlorothiazide is a
sulphonamide-derived medicinal product).
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
• Cholestasis and biliary obstructive disorders.
• Severe hepatic impairment.
• Severe renal impairment (creatinine clearance < 30 ml/min).
• Refractory hypokalaemia, hypercalcaemia.
The concomitant use of Lisart Plus with aliskiren-containing products is contraindicated in patients with
diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin<br />II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to<br />alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately,<br />and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Hepatic impairment</u><br />Lisart Plus should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic<br />insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile. These patients can be<br />expected to have reduced hepatic clearance for telmisartan.<br />In addition, Lisart Plus should be used with caution in patients with impaired hepatic function or<br />progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic<br />coma. There is no clinical experience with Lisart Plus in patients with hepatic impairment.</p><p><u>Renovascular hypertension</u><br />There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal<br />artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products<br />that affect the renin-angiotensin-aldosterone system.</p><p><u>Renal impairment and kidney transplantation</u><br />Lisart Plus should not be used in patients with severe renal impairment (creatinine clearance &lt;30 ml/min)<br />(see section 4.3). There is no experience regarding the administration of Lisart Plus in patients with recent<br />kidney transplantation. Experience with Lisart Plus is modest in the patients with mild to moderate renal<br />impairment, therefore periodic monitoring of potassium, creatinine and uric acid serum levels is<br />recommended. Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function.</p><p><u>Intravascular hypovolaemia</u><br />Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or<br />sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such<br />conditions should be corrected before the administration of Lisart Plus.</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u><br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren<br />increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal<br />failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor<br />blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade therapy is<br />considered absolutely necessary, this should only occur under specialist supervision and subject to frequent<br />close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II<br />receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><u>Other conditions with stimulation of the renin-angiotensin-aldosterone system</u><br />In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-<br />aldosterone system (e.g. patients with severe congestive heart failure or underlying renal<br />disease, including renal artery stenosis), treatment with medicinal products that affect this system has been<br />associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8).</p><p><u>Primary aldosteronism</u><br />Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products<br />acting through inhibition of the renin-angiotensin system. Therefore, the use of Lisart Plus is not<br />recommended.</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</u><br />As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis,<br />or obstructive hypertrophic cardiomyopathy.</p><p><u>Metabolic and endocrine effects</u><br />Thiazide therapy may impair glucose tolerance, whereas hypoglycaemia may occur in diabetic patients<br />under insulin or antidiabetic therapy and telmisartan treatment. Therefore, in these patients blood glucose<br />monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required, when<br />indicated. Latent diabetes mellitus may become manifest during thiazide therapy.<br />An increase in cholesterol and triglyceride levels has been associated with thiazide diuretic therapy;<br />however, at the 12.5 mg dose contained in Lisart Plus, minimal or no effects were reported.<br />Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide therapy.</p><p><u>Electrolyte imbalance</u><br />As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be<br />performed at appropriate intervals.<br />Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including<br />hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or electrolyte<br />imbalance are dryness of mouth, thirst, asthenia, lethargy, drowsiness, restlessness, muscle pain or cramps,<br />muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or<br />vomiting (see section 4.8).</p><p>- Hypokalaemia<br />Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with telmisartan<br />may reduce diuretic-induced hypokalaemia. The risk of hypokalaemia is greater in patients with cirrhosis of<br />liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of<br />electrolytes and in patients receiving concomitant therapy with corticosteroids or Adrenocorticotropic<br />hormone (ACTH) (see section 4.5).<br />- Hyperkalaemia<br />Conversely, due to the antagonism of the angiotensin II (AT1) receptors by the telmisartan component of<br />Lisart Plus, hyperkalaemia might occur. Although clinically significant hyperkalaemia has not been<br />documented with Lisart Plus, risk factors for the development of hyperkalaemia include renal insufficiency<br />and/or heart failure, and diabetes mellitus. Potassium-sparing diuretics, potassium supplements or<br />potassium-containing salt substitutes should be co-administered cautiously with Lisart Plus (see section<br />4.5).</p><p>- Hyponatraemia and hypochloraemic alkalosis<br />There is no evidence that Lisart Plus would reduce or prevent diuretic-induced hyponatraemia. Chloride<br />deficit is generally mild and usually does not require treatment.<br />- Hypercalcaemia<br />Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum<br />calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be<br />evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for<br />parathyroid function.<br />- Hypomagnesaemia<br />Thiazides have been shown to increase the urinary excretion of magnesium, which may result in<br />hypomagnesaemia (see section 4.5).</p><p><u>Sorbitol and Lactose Monohydrate</u><br />This medicinal product contains lactose monohydrate and sorbitol. Patients with rare hereditary problems<br />of fructose intolerance and/or with rare hereditary problems of galactose intolerance, the Lapp lactase<br />deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><u>Ethnic differences</u><br />As with all other angiotensin II receptor antagonists, telmisartan is apparently less effective in lowering<br />blood pressure in black patients than in non blacks, possibly because of higher prevalence of low renin<br />states in the black hypertensive population.</p><p><u>Other</u><br />As with any antihypertensive agent, excessive reduction of blood pressure in patients with ischaemic<br />cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</p><p><u>General</u><br />Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy<br />or bronchial asthma, but are more likely in patients with such a history.<br />Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide<br />diuretics, including hydrochlorothiazide.<br />Cases of photosensitivity reactions have been reported with thiazide diuretics (see section 4.8). If a<br />photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or<br />to artificial UVA.</p><p><u>Acute Myopia and Angle-Closure Glaucoma</u><br />Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia<br />and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain<br />and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can<br />lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as<br />possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure<br />remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of<br />sulfonamide or penicillin allergy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Lithium</u><br />Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant<br />administration of lithium with angiotensin converting enzyme inhibitors. Rare cases have also been<br />reported with angiotensin II receptor antagonists (including Lisart Plus). Co-administration of lithium and<br />Lisart Plus is not recommended (see section 4.4). If this combination proves essential, careful monitoring<br />of serum lithium level is recommended during concomitant use.</p><p><u>Medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics,</u><br />laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid and<br />derivatives)If these substances are to be prescribed with the hydrochlorothiazide-telmisartan combination, monitoring<br />of potassium plasma levels is advised. These medicinal products may potentiate the effect of<br />hydrochlorothiazide on serum potassium (see section 4.4).</p><p><u>Medicinal products that may increase potassium levels or induce hyperkalaemia</u> (e.g. ACE inhibitors,<br />potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, cyclosporin or<br />other medicinal products such as heparin sodium)<br />If these medicinal products are to be prescribed with the hydrochlorothiazide-telmisartan combination,<br />monitoring of potassium plasma levels is advised. Based on the experience with the use of other medicinal<br />products that blunt the renin- angiotensin system, concomitant use of the above medicinal products may<br />lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).</p><p><u>Medicinal products affected by serum potassium disturbances</u><br />Periodic monitoring of serum potassium and ECG is recommended when Lisart Plus is administered with<br />medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics)<br />and the following torsades de pointes inducing medicinal products (which include some antiarrhythmics),<br />hypokalaemia being a predisposing factor to torsades de pointes.<br />- class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide)<br />- class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide)<br />- some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine,<br />sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol)<br />- others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine,<br />sparfloxacine, terfenadine, vincamine IV.)</p><p><u>Digitalis glycosides</u><br />Thiazide-induced hypokalaemia or hypomagnesaemia favours the onset of digitalis-induced arrhythmia<br />(see section 4.4).</p><p><u>Digoxin</u><br />When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma<br />concentration (49%) and in trough concentration (20%) were observed. When initiating, adjusting, and<br />discontinuing telmisartan, monitor digoxin levels in order to maintain levels within the therapeutic range.</p><p><u>Other antihypertensive agents</u><br />Telmisartan may increase the hypotensive effect of other antihypertensive agents.<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS)<br />through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with<br />a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function<br />(including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and<br />5.1).</p><p><u>Antidiabetic medicinal products (oral agents and insulin)</u><br />Dosage adjustment of the antidiabetic medicinal products may be required (see section 4.4).</p><p><u>Metformin</u><br />Metformin should be used with precaution: risk of lactic acidosis induced by a possible functional renal<br />failure linked to hydrochlorothiazide.</p><p><u>Cholestyramine and colestipol resins</u><br />Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.</p><p><u>Non-steroidal anti-inflammatory medicinal products</u><br />NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and nonselective<br />NSAIDs) may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics and<br />the antihypertensive effects of angiotensin II receptor antagonists.<br />In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with<br />compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that<br />inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal<br />failure, which is usually reversible. Therefore the combination should be administered with caution,</p><p>especially in the elderly. Patients should be adequately hydrated and consideration should be given to<br />monitoring of renal function after initiation of concomitant therapy and periodically thereafter.<br />In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the<br />AUC0-24 and Cmax of ramipril and ramiprilat. The clinical relevance of this observation is not known.</p><p><u>Pressor amines (e.g. noradrenaline)</u><br />The effect of pressor amines may be decreased.</p><p><u>Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine)</u><br />The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.</p><p><u>Medicinal products used in the treatment for gout (e.g. probenecid, sulfinpyrazone and allopurinol)</u><br />Dosage adjustment of uricosuric medications may be necessary as hydrochlorothiazide may raise the level<br />of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration<br />of thiazide may increase the incidence of hypersensitivity reactions of allopurinol.</p><p><u>Calcium salts</u><br />Thiazide diuretics may increase serum calcium levels due to the decreased excretion. If calcium<br />supplements must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted<br />accordingly.</p><p><u>Beta-blockers and diazoxide</u><br />The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p><u>Anticholinergic agents </u>(e.g. atropine, biperiden) may increase the bioavailability of thiazide-type diuretics<br />by decreasing gastrointestinal motility and stomach emptying rate.</p><p><u>Amantadine</u><br />Thiazides may increase the risk of adverse effects caused by amantadine.</p><p><u>Cytotoxic agents (e.g. cyclophosphamide, methotrexate)</u><br />Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their<br />myelosuppressive effects.<br />Based on their pharmacological properties it can be expected that the following medicinal products may<br />potentiate the hypotensive effects of all antihypertensives including telmisartan: Baclofen, amifostine.<br />Furthermore, orthostatic hypotension may be aggravated by alcohol, barbiturates, narcotics or<br />antidepressants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy<br />(see section 4.4). The use of angiotensin II receptor antagonists is contraindicated during the second and<br />third trimesters of pregnancy (see sections 4.3 and 4.4).</p><p>There are no adequate data from the use of Lisart Plus in pregnant women. Studies in animals have shown<br />reproductive toxicity (see section 5.3).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during<br />the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be<br />excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor<br />antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin II receptor<br />antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative<br />antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy<br />is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if<br />appropriate, alternative therapy should be started.</p><p>Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to<br />induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and<br />neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</p><p>Should exposure to angiotensin II receptor antagonists have occurred from the second trimester of<br />pregnancy, ultrasound check of renal function and skull is recommended.<br />Infants whose mothers have taken angiotensin II receptor antagonists should be closely observed for<br />hypotension (see sections 4.3 and 4.4).<br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the first<br />trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the<br />pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester<br />may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus,<br />disturbance of electrolyte balance and thrombocytopenia.<br />Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia<br />due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the<br />course of the disease.<br />Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare<br />situations where no other treatment could be used.<br /><u>Breast-feeding</u><br />Because no information is available regarding the use of Lisart Plus during breast-feeding, Lisart Plus is not<br />recommended and alternative treatments with better established safety profiles during breast-feeding are<br />preferable, especially while nursing a newborn or preterm infant.<br />Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense<br />diuresis can inhibit the milk production. The use of Lisart Plus during breast feeding is not recommended.<br />If Lisart Plus is used during breast feeding, doses should be kept as low as possible.<br /><u>Fertility</u><br />In preclinical studies, no effects of telmisartan and hydrochlorothiazide on male and female fertility were<br />observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness<br />may occasionally occur when taking antihypertensive therapy such as Lisart Plus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u><br />The most commonly reported adverse reaction is dizziness. Serious angioedema may occur rarely<br />(1/10,000 to &lt;1/1,000). The overall incidence of adverse reactions reported with LisartPlus was<br />comparable to those reported with telmisartan alone in randomised controlled trials involving 1471 patients<br />randomised to receive telmisartan plus hydrochlorothiazide (835) or telmisartan alone (636). Doserelationship<br />of adverse reactions was not established and they showed no correlation with gender, age or<br />race of the patients.</p><p><u>Tabulated summary of adverse reactions</u><br />Adverse reactions reported in all clinical trials and occurring more frequently (p 0.05) with telmisartan<br />plus hydrochlorothiazide than with placebo are shown below according to system organ class. Adverse<br />reactions known to occur with each component given singly but which have not been seen in clinical trials<br />may occur during treatment with LisartPlus.<br />Adverse reactions have been ranked under headings of frequency using the following convention: very<br />common (1/10); common (1/100 to &lt;1/10); uncommon (1/1,000 to &lt;1/100); rare (1/10,000 to<br />&lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).<br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />Infections and infestations<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Bronchitis, pharyngitis, sinusitis<br />Immune system disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Exacerbation or activation of systemic lupus erythematosus1<br />Metabolism and nutrition disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hypokalaemia<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hyperuricaemia, hyponatraemia<br />Psychiatric disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Anxiety<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Depression<br />Nervous system disorders<br />Common:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Dizziness<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp; Syncope, paraesthesia<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Insomnia, sleep disorders<br />Eye disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Visual disturbance, vision blurred<br />Ear and labyrinth disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp;Vertigo<br />Cardiac disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp; Tachycardia, arrhythmias<br />Vascular disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp;Hypotension, orthostatic hypotension<br />Respiratory,&nbsp;thoracic and mediastinal disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp;Dyspnoea<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Respiratory distress (including pneumonitis and pulmonary oedema)<br />Gastrointestinal disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; Diarrhoea, dry mouth, flatulence<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Abdominal pain, constipation, dyspepsia, vomiting, gastritis<br />Hepatobiliary disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Abnormal hepatic function/liver disorder2<br />Skin and subcutaneous tissue disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Angioedema (also with fatal outcome), erythema, pruritus, rash, hyperhidrosis,urticaria<br />Muscoloskeletal, connective tissue and bone disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; Back pain, muscle spasms, myalgia<br />Rare:&nbsp; &nbsp; &nbsp;Arthralgia, muscle cramps, pain in limb<br />Reproductive system and breast disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp;Erectile dysfunction<br />General disorders and administration site conditions<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Chest pain<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Influenza-like illness, pain<br />Investigations<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Blood uric acid increased<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Blood creatinine increased, blood creatine phosphokinase increased, hepatic enzyme<br />increased<br />1: Based on post-marketing experience<br />2: For further description, please see sub-section &ldquo;Description of selected adverse reactions&rdquo;<br />Additional information on individual components<br />Adverse reactions previously reported with one of the individual components may be potential adverse<br />reactions with LisartPlus, even if not observed in clinical trials with this product.</p><p>Telmisartan:<br />Adverse reactions occurred with similar frequency in placebo and telmisartan treated patients.<br />The overall incidence of adverse reactions reported with telmisartan (41.4 %) was usually comparable to<br />placebo (43.9 %) in placebo controlled trials. The following adverse reactions listed below have been<br />accumulated from all clinical trials in patients treated with telmisartan for hypertension or in patients 50<br />years or older at high risk of cardiovascular events.<br />Infections and infestations<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Upper respiratory tract infection, urinary tract infection including cystitis<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Sepsis including fatal outcome3<br />Blood and lymphatic system disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp; Anaemia<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Eosinophilia, thrombocytopenia<br />Immune system disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hypersensitivity, anaphylactic reactions<br />Metabolism and nutrition disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; Hyperkalaemia<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hypoglycaemia (in diabetic patients)<br />Cardiac disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; Bradycardia<br />Nervous system disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Somnolence<br />Respiratory, thoracic and mediastinal disorders<br />Uncommon:&nbsp; &nbsp; &nbsp; Cough<br />Very rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Interstitial lung disease3<br />Gastrointestinal disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Stomach discomfort<br />Skin and subcutaneous tissue disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Eczema, drug eruption, toxic skin eruption<br />Musculoskeletal, connective tissue and bone disorders<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Arthrosis, tendon pain<br />Renal and urinary disorders<br />Uncommon:&nbsp; &nbsp; Renal impairment (including acute renal failure)<br />General disorders and administration site conditions<br />Uncommon:&nbsp; &nbsp; &nbsp;Asthenia<br />Investigations<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp;Haemoglobin decreased<br />3: For further description, please see sub-section &ldquo;Description of selected adverse reactions&rdquo;<br />Hydrochlorothiazide:<br />Hydrochlorothiazide may cause or exacerbate hypovolaemia which could lead to electrolyte imbalance (see<br />section 4.4).<br />Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include:<br />Infections and infestations<br />Not known:&nbsp; &nbsp; Sialadenitis<br />Blood and lymphatic system disorders<br />Not known:&nbsp; &nbsp; &nbsp;Aplastic anaemia, haemolytic anaemia, bone marrow failure, leukopenia, neutropenia, agranulocytosis, thrombocytopenia<br />Immune system disorders<br />Not known: Anaphylactic reactions, hypersensitivity<br />Endocrine disorders<br />Not known:&nbsp; &nbsp; &nbsp; &nbsp; Diabetes mellitus inadequate control<br />Metabolism and nutrition disorders<br />Not known:&nbsp; &nbsp; &nbsp; &nbsp; Anorexia, appetite decreased, electrolyte imbalance, hypercholesterolaemia, hyperglycaemia, hypovolaemia<br />Psychiatric disorders<br />Not known:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Restlessness<br />Nervous system disorders<br />Not known:&nbsp; &nbsp; &nbsp;Light-headedness<br />Eye disorders<br />Not known&nbsp; &nbsp;Xanthopsia, acute myopia, acute angle-closure glaucoma<br />Vascular disorders<br />Not known:&nbsp; &nbsp; Vasculitis necrotizing<br />Gastrointestinal disorders<br />Not known:&nbsp; &nbsp; Pancreatitis, stomach discomfort<br />Hepatobiliary disorders<br />Not known:&nbsp; &nbsp;Jaundice hepatocellular, jaundice cholestatic<br />Skin and subcutaneous tissue disorders<br />Not known:&nbsp; &nbsp;Lupus-like syndrome, photosensitivity reactions, skin vasculitis, toxic epidermal ,necrolysis<br />Musculoskeletal, connective tissue and bone disorders<br />Not known:&nbsp; &nbsp; Weakness<br />Renal and urinary disorders<br />Not known:&nbsp; &nbsp; &nbsp;Nephritis interstitial, renal dysfunction, glycosuria<br />General disorders and administration site conditions<br />Not known:&nbsp; &nbsp; &nbsp;Pyrexia<br />Investigations<br />Not known:&nbsp; &nbsp; Triglycerides increased<br /><u>Description of selected adverse reactions<br />Hepatic function abnormal / liver disorder</u><br />Most cases of hepatic function abnormal / liver disorder from post-marketing experience with telmisartan<br />occurred in Japanese patients. Japanese patients are more likely to experience these adverse reactions.<br /><u>Sepsis</u></p><p>In the PRoFESS trial, an increased incidence of sepsis was observed with telmisartan compared with<br />placebo. The event may be a chance finding or related to a mechanism currently not known (see section<br />5.1).</p><p><u>Interstitial lung disease</u><br />Cases of interstitial lung disease have been reported from post-marketing experience in temporal<br />association with the intake of telmisartan. However, a causal relationship has not been established.<br />To report any side effects:<br />o Fax: +966-11-205-7662<br />o To contact national Pharmacovigilance management: +966-11-2038222 ext.: 2353 &ndash; 2356 &ndash; 2317 &ndash;<br />2354 &ndash; 2334 &ndash; 2340<br />o Toll-free: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available for telmisartan with regard to overdose in humans. The degree to<br />which hydrochlorothiazide is removed by haemodialysis has not been established.<br /><u>Symptoms</u><br />The most prominent manifestations of telmisartan overdose were hypotension and tachycardia;<br />bradycardia, dizziness, vomiting, increase in serum creatinine, and acute renal failure have also been<br />reported. Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,<br />hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and<br />symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and/or<br />accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic<br />medicinal products.<br /><u>Treatment</u><br />Telmisartan is not removed by haemodialysis. The patient should be closely monitored, and the treatment<br />should be symptomatic and supportive. Management depends on the time since ingestion and the severity<br />of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal<br />may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored<br />frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume<br />replacements given quickly.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, ATC code: C09DA07<br />LisartPlus is a combination of an angiotensin II receptor antagonist, telmisartan, and a thiazide diuretic,<br />hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing<br />blood pressure to a greater degree than either component alone. LisartPlus once daily produces effective<br />and smooth reductions in blood pressure across the therapeutic dose range.<br />Telmisartan is an orally effective and specific angiotensin II receptor subtype 1 (AT1) antagonist.<br />Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor<br />subtype, which is responsible for the known actions of angiotensin II. Telmisartan does not exhibit any<br />partial agonist activity at the AT1 receptor. Telmisartan selectively binds the AT1 receptor. The binding is<br />long-lasting. Telmisartan does not show affinity for other receptors, including AT2 and other less<br />characterised AT receptors. The functional role of these receptors is not known, nor is the effect of their<br />possible overstimulation by angiotensin II, whose levels are increased by telmisartan. Plasma aldosterone<br />levels are decreased by telmisartan. Telmisartan does not inhibit human plasma renin or block ion channels.<br />Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades<br />bradykinin. Therefore, it is not expected to potentiate bradykinin-mediated adverse effects.<br />An 80 mg dose of telmisartan administered to healthy volunteers almost completely inhibits the angiotensin<br />II evoked blood pressure increase. The inhibitory effect is maintained over 24 hours and still measurable up<br />to 48 hours.<br />After the first dose of telmisartan, the antihypertensive activity gradually becomes evident within 3 hours.<br />The maximum reduction in blood pressure is generally attained 4-8 weeks after the start of treatment and is<br />sustained during long-term therapy. The antihypertensive effect persists constantly over 24 hours after<br />dosing and includes the last 4 hours before the next dose as shown by ambulatory blood pressure<br />measurements. This is confirmed by measurements made at the point of maximum effect and immediately<br />prior to the next dose (through to peak ratios consistently above 80 % after doses of 40 and 80 mg of<br />telmisartan in placebo controlled clinical studies).<br />In patients with hypertension telmisartan reduces both systolic and diastolic blood pressure without<br />affecting pulse rate. The antihypertensive efficacy of telmisartan is comparable to that of agents<br />representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials<br />comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril).<br />Upon abrupt cessation of treatment with telmisartan, blood pressure gradually returns to pre-treatment<br />values over a period of several days without evidence of rebound hypertension.<br />The incidence of dry cough was significantly lower in patients treated with telmisartan than in those given<br />angiotensin converting enzyme inhibitors in clinical trials directly comparing the two antihypertensive<br />treatments.<br />Cardiovascular prevention<br />ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial)<br />compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on<br />cardiovascular outcomes in 25620 patients aged 55 years or older with a history of coronary artery disease,<br />stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ<br />damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population<br />at risk for cardiovascular events.<br />Patients were randomized to one of the three following treatment groups: telmisartan 80 mg (n = 8542),<br />ramipril 10 mg (n = 8576), or the combination of telmisartan 80 mg plus ramipril 10 mg (n = 8502), and<br />followed for a mean observation time of 4.5 years.<br />Telmisartan showed a similar effect to ramipril in reducing the primary composite endpoint of<br />cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive<br />heart failure. The incidence of the primary endpoint was similar in the telmisartan (16.7 %) and ramipril<br />(16.5 %) groups. The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5 % CI 0.93 - 1.10, p (noninferiority)<br />= 0.0019 at a margin of 1.13). The all-cause mortality rate was 11.6 % and 11.8 % among<br />telmisartan and ramipril treated patients, respectively.<br />Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of<br />cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.90 - 1.08), p<br />(non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes<br />Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.<br />TRANSCEND randomized ACE-I intolerant patients with otherwise similar inclusion criteria as<br />ONTARGET to telmisartan 80 mg (n=2954) or placebo (n=2972), both given on top of standard care. The<br />mean duration of follow up was 4 years and 8 months. No statistically significant difference in the<br />incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, nonfatal<br />stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 %<br />in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)]. There was evidence for a<br />benefit of telmisartan compared to placebo in the pre-specified secondary composite endpoint of<br />cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.87 (95 % CI 0.76 - 1.00, p =<br />0.048)]. There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 -<br />1.24).<br />Cough and angioedema were less frequently reported in patients treated with telmisartan than in patients<br />treated with ramipril, whereas hypotension was more frequently reported with telmisartan.<br />Combining telmisartan with ramipril did not add further benefit over ramipril or telmisartan alone. CV<br />mortality and all cause mortality were numerically higher with the combination. In addition, there was a<br />significantly higher incidence of hyperkalaemia, renal failure, hypotension and syncope in the combination<br />arm. Therefore the use of a combination of telmisartan and ramipril is not recommended in this population.<br />In the &quot;Prevention Regimen For Effectively avoiding Second Strokes&quot; (PRoFESS) trial in patients 50 years<br />and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan<br />compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence<br />of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16<br />%) [RR 2.07 (95 % confidence interval 1.14 - 3.76)]. The observed increased occurrence rate of sepsis<br />associated with the use of telmisartan may be either a chance finding or related to a mechanism not<br />currently known.<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination<br />with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in<br />Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor<br />blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease,<br />or type 2 diabetes mellitus accompanied by evidence of end-organ damage. For more detailed information<br />see above under the heading &ldquo;Cardiovascular prevention&rdquo;. VA NEPHRON-D was a study in patients with<br />type 2 diabetes mellitus and diabetic nephropathy. These studies have shown no significant beneficial effect<br />on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute<br />kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar<br />pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II<br />receptor blockers. ACE-inhibitors and angiotensin II receptor blockers should therefore not be used<br />concomitantly in patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a<br />study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an<br />angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease,<br />cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse<br />outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than<br />in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension<br />and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.<br />Hydrochlorothiazide is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide<br />diuretics is not fully known. Thiazides have an effect on the renal tubular mechanisms of electrolyte<br />reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts.<br />The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity,<br />increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and<br />decreases in serum potassium. Presumably through blockade of the renin-angiotensin-aldosterone system,<br />co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics. With<br />hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while the<br />action persists for approximately 6-12 hours.<br />Epidemiological studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of<br />cardiovascular mortality and morbidity.<br />The effects of fixed dose combination of telmisartan/HCTZ on mortality and cardiovascular morbidity are<br />currently unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of hydrochlorothiazide and telmisartan does not appear to affect the<br />pharmacokinetics of either substance in healthy subjects.<br /><u>Absorption</u><br />Telmisartan: Following oral administration peak concentrations of telmisartan are reached in 0.5 &ndash; 1.5 h<br />after dosing. The absolute bioavailability of telmisartan at 40 mg and 160 mg was 42 % and 58 %,<br />respectively. Food slightly reduces the bioavailability of telmisartan with a reduction in the area under the<br />plasma concentration time curve (AUC) of about 6 % with the 40 mg tablet and about 19 % after a 160 mg<br />dose. By 3 hours after administration plasma concentrations are similar whether telmisartan is taken fasting<br />or with food. The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy.<br />The pharmacokinetics of orally administered telmisartan are non-linear over doses from 20 &ndash; 160 mg with<br />greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.<br />Telmisartan does not accumulate significantly in plasma on repeated administration.<br />Hydrochlorothiazide: Following oral administration of LisartPlus peak concentrations of<br />hydrochlorothiazide are reached in approximately 1.0 &ndash; 3.0 hours after dosing. Based on cumulative renal<br />excretion of hydrochlorothiazide the absolute bioavailability was about 60 %.<br /><u>Distribution</u><br />Telmisartan is highly bound to plasma proteins (&gt;99.5 %) mainly albumin and alpha 1- acid glycoprotein.<br />The apparent volume of distribution for telmisartan is approximately 500 litres indicating additional tissue<br />binding.<br />Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 &ndash;<br />1.14 l/kg.<br /><u>Biotransformation</u><br />Telmisartan is metabolised by conjugation to form a pharmacologically inactive acylglucuronide. The<br />glucuronide of the parent compound is the only metabolite that has been identified in humans. After a<br />single dose of 14C-labelled telmisartan the glucuronide represents approximately 11 % of the measured<br />radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of<br />telmisartan.<br />Hydrochlorothiazide is not metabolised in man.<br /><u>Elimination</u><br />Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the<br />administered dose (&gt;97 %) was eliminated in faeces via biliary excretion. Only minute amounts were found<br />in urine. Total plasma clearance of telmisartan after oral administration is &gt;1500 ml/min. Terminal<br />elimination half-life was &gt;20 hours.<br />Hydrochlorothiazide is excreted almost entirely as unchanged substance in urine. About 60 % of the oral<br />dose is eliminated within 48 hours. Renal clearance is about 250 &ndash; 300 ml/min. The terminal elimination<br />half-life of hydrochlorothiazide is 10 &ndash; 15 hours.<br />Special populations<br /><u>Elderly</u><br />Pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.<br /><u>Gender</u><br />Plasma concentrations of telmisartan are generally 2 &ndash; 3 times higher in females than in males. In clinical<br />trials however, no significant increases in blood pressure response or in the incidence of orthostatic<br />hypotension were found in women. No dosage adjustment is necessary. There was a trend towards higher<br />plasma concentrations of hydrochlorothiazide in female than in male subjects. This is not considered to be<br />of clinical relevance.<br /><u>Renal impairment</u><br />Renal excretion does not contribute to the clearance of telmisartan. Based on modest experience in patients<br />with mild to moderate renal impairment (creatinine clearance of 30 &ndash; 60 ml/min, mean about 50 ml/min) no<br />dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from<br />blood by haemodialysis. In patients with impaired renal function the rate of hydrochlorothiazide<br />elimination is reduced. In a typical study in patients with a mean creatinine clearance of 90 ml/min the<br />elimination half-life of hydrochlorothiazide was increased. In functionally anephric patients the elimination<br />half-life is about 34 hours.<br /><u>Hepatic impairment</u><br />Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability<br />up to nearly 100 %. The elimination half-life is not changed in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical safety studies performed with co-administration of telmisartan and hydrochlorothiazide in<br />normotensive rats and dogs, doses producing exposure comparable to that in the clinical therapeutic range<br />caused no additional findings not already observed with administration of either substance alone. The<br />toxicological findings observed appear to have no relevance to human therapeutic use.<br />Toxicological findings also well known from preclinical studies with angiotensin converting enzyme<br />inhibitors and angiotensin II receptor antagonists were: a reduction of red cell parameters (erythrocytes,<br />haemoglobin, haematocrit), changes of renal haemodynamics (increased blood urea nitrogen and<br />creatinine), increased plasma renin activity, hypertrophy/hyperplasia of the juxtaglomerular cells and<br />gastric mucosal injury. Gastric lesions could be prevented/ameliorated by oral saline supplementation and<br />group housing of animals. In dogs renal tubular dilation and atrophy were observed. These findings are<br />considered to be due to the pharmacological activity of telmisartan.<br />No clear evidence of a teratogenic effect was observed, however at toxic dose levels of telmisartan an<br />effect on the postnatal development of the offsprings such as lower body weight and delayed eye opening<br />was observed.<br />Telmisartan showed no evidence of mutagenicity and relevant clastogenic activity in in vitro studies and no<br />evidence of carcinogenicity in rats and mice. Studies with hydrochlorothiazide have shown equivocal<br />evidence for a genotoxic or carcinogenic effect in some experimental models. However, the extensive<br />human experience with hydrochlorothiazide has failed to show an association between its use and an<br />increase in neoplasms. For the foetotoxic potential of the telmisartan/hydrochlorothiazide combination see<br />section 4.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Povidone<br />Meglumine<br />Sodium Hydroxide<br />Magnesium Stearate<br />Lactose Monohydrate<br />Microcrystalline Cellulose<br />Maize Starch<br />Sodium Starch Glycolate (Type A)<br />Iron Oxide Red (Sicovit Red 30E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30oC<br />Store in the original pack to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LISART PLUS TABLET 40 mg/12.5mg Tablets are packed in Alu / Alu Blister as 7 tablets per blister and 28<br />tablets per pack.<br />LISART PLUS TABLET 80 mg/12.5mg Tablets are packed in Alu / Alu Blister as 7 tablets per blister and 28<br />tablets per pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing
authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>